Cellular Therapy for Treatment of Virally-Induced ARDS
At A Glance
Validus Cellular Therapeutics is advancing technology developed at Colorado State University based on proprietary activation of mesenchymal stem cells (MSC) and their application to treatment of resistant bacterial infections. Since viral pneumonia, such as that related to COVID-19, often leads to difficult to treat bacterial pneumonia, the technology has application to treatment of seriously ill COVID-19 patients.
Reference No.: 16-022
Many bacterial infections are unresponsive to typical antibacterial drugs. The lack of response is often not due to the emergence of drug-resistant strains of bacteria (e.g. MRSA), but to a variety of other mechanisms. For example, not only can biofilm production isolate bacteria from treatment, but also poorly vascularized tissues can inhibit delivery of treatment, such as the case with orthopedic joint replacement. As a result, there is often no good treatment option available – leading to poor outcomes for patients.
Using proprietary activation of mesenchymal stem cells (allogenic), storage, and dosing, Validus Cellular Therapeutics has advanced product into cGMP production of cells for use in human clinical studies.
- Can be scaled
- Steps to activate and administer MSC as a therapeutic; similar to other stem cell technologies evaluated in human clinical trials, and commercialized
- Has demonstrated impressive clinical activity in canine drug resistant infections
- Offers a broad-spectrum solution to the problem of drug resistant infections
- Treatment of highly resistant bacterial infections, including biofilm infections
Last updated: April 2020